Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.56 |
| ▸ | MMP9 | P14780 | 16/20 | 0.56 |
| ▸ | MMP3 | P08254 | 5/20 | 0.52 |
| ▸ | MMP1 | P03956 | 3/20 | 0.52 |
| ▸ | MMP8 | P22894 | 3/20 | 0.52 |
| ▸ | MMP14 | P50281 | 3/20 | 0.52 |
| ▸ | MMP25 | Q9NPA2 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13272367 | 0.81 | MMP9 (0.63) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL22279651 | 0.74 | MMP9 (0.79) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL22266001 | 0.74 | MMP9 (0.79) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL13272163 | 0.70 | MMP9 (0.54) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL14823005 | 0.69 | MMP9 (0.65) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL5821059 | 0.68 | MMP9 (0.47) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL3691573 | 0.67 | MMP9 (0.61) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL13409998 | 0.67 | MMP9 (0.61) | MMP2MMP9MMP3MMP1MMP8 | |
| SCHEMBL3641034 | 0.66 | FFAR1 (0.56) | MAPT | |
| SCHEMBL3641032 | 0.66 | FFAR1 (0.56) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020154243-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISORDERS | AQUILUS PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |